AR and prostate cancer: While TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells, sGC inhibitor treatment repressed tumor growth in TMPRSS2-ERG-positive VCaP xenograft models and acted in synergy with enzalutamide, the potent AR antagonist (Zhou et al., 2019).